Concomitant Kinase-Dead BRAF and Oncogenic KRAS Lead to an Aggressive Biologic Behavior and Tumor Lysis Syndrome: A Case Report
Tumor lysis syndrome (TLS) is a life-threatening oncological emergency rarely seen in solid tumors and is a complication of cancer therapy for rapidly proliferating tumors with devastating outcomes. BRAF and KRAS are two key oncogenes in the MAPK signaling pathway that are routinely examined for mut...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-05-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.885814/full |
| _version_ | 1811304511084429312 |
|---|---|
| author | Roy Holland Offir Ben-Ishay Offir Ben-Ishay Irit Ben-Aharon Irit Ben-Aharon Irit Ben-Aharon |
| author_facet | Roy Holland Offir Ben-Ishay Offir Ben-Ishay Irit Ben-Aharon Irit Ben-Aharon Irit Ben-Aharon |
| author_sort | Roy Holland |
| collection | DOAJ |
| description | Tumor lysis syndrome (TLS) is a life-threatening oncological emergency rarely seen in solid tumors and is a complication of cancer therapy for rapidly proliferating tumors with devastating outcomes. BRAF and KRAS are two key oncogenes in the MAPK signaling pathway that are routinely examined for mutations to predict resistance to anti-EGFR therapy. Concomitant KRAS and BRAF mutations in GI tumors are rare, occurring in less than 0.001% of cases and are associated with an aggressive tumor behavior. We report an unusual case of a young male patient diagnosed with locally advanced duodenal mucinous adenocarcinoma harboring concomitant KRAS and BRAF mutations. This unique genetic profile generated hyperactivation of the EGFR signaling pathway. Following day-1 of mFOLFOX-6 chemotherapy protocol, the patient developed TLS. Clinical resolution was achieved using high volume hydration. Unfortunately, the patient passed away 10 days later during anesthesia induction. |
| first_indexed | 2024-04-13T08:08:27Z |
| format | Article |
| id | doaj.art-d6b2d3c385fc4befa0d6ecfe4a8f51a2 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-13T08:08:27Z |
| publishDate | 2022-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-d6b2d3c385fc4befa0d6ecfe4a8f51a22022-12-22T02:55:06ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-05-011210.3389/fonc.2022.885814885814Concomitant Kinase-Dead BRAF and Oncogenic KRAS Lead to an Aggressive Biologic Behavior and Tumor Lysis Syndrome: A Case ReportRoy Holland0Offir Ben-Ishay1Offir Ben-Ishay2Irit Ben-Aharon3Irit Ben-Aharon4Irit Ben-Aharon5Division of Oncology, Rambam Health Care Campus, Haifa, IsraelDivision of Surgery, Rambam Health Care Campus, Haifa, IsraelRappaport Faculty of Medicine, Technion, Haifa, IsraelDivision of Oncology, Rambam Health Care Campus, Haifa, IsraelRappaport Faculty of Medicine, Technion, Haifa, IsraelTechnion-Integrated Cancer Center, Technion, Haifa, IsraelTumor lysis syndrome (TLS) is a life-threatening oncological emergency rarely seen in solid tumors and is a complication of cancer therapy for rapidly proliferating tumors with devastating outcomes. BRAF and KRAS are two key oncogenes in the MAPK signaling pathway that are routinely examined for mutations to predict resistance to anti-EGFR therapy. Concomitant KRAS and BRAF mutations in GI tumors are rare, occurring in less than 0.001% of cases and are associated with an aggressive tumor behavior. We report an unusual case of a young male patient diagnosed with locally advanced duodenal mucinous adenocarcinoma harboring concomitant KRAS and BRAF mutations. This unique genetic profile generated hyperactivation of the EGFR signaling pathway. Following day-1 of mFOLFOX-6 chemotherapy protocol, the patient developed TLS. Clinical resolution was achieved using high volume hydration. Unfortunately, the patient passed away 10 days later during anesthesia induction.https://www.frontiersin.org/articles/10.3389/fonc.2022.885814/fulltumor lysis syndromecase reportconcomitant BRAF and KRAS mutationsduodenal mucinous adenocarcinomaNGS - next generation sequencing |
| spellingShingle | Roy Holland Offir Ben-Ishay Offir Ben-Ishay Irit Ben-Aharon Irit Ben-Aharon Irit Ben-Aharon Concomitant Kinase-Dead BRAF and Oncogenic KRAS Lead to an Aggressive Biologic Behavior and Tumor Lysis Syndrome: A Case Report Frontiers in Oncology tumor lysis syndrome case report concomitant BRAF and KRAS mutations duodenal mucinous adenocarcinoma NGS - next generation sequencing |
| title | Concomitant Kinase-Dead BRAF and Oncogenic KRAS Lead to an Aggressive Biologic Behavior and Tumor Lysis Syndrome: A Case Report |
| title_full | Concomitant Kinase-Dead BRAF and Oncogenic KRAS Lead to an Aggressive Biologic Behavior and Tumor Lysis Syndrome: A Case Report |
| title_fullStr | Concomitant Kinase-Dead BRAF and Oncogenic KRAS Lead to an Aggressive Biologic Behavior and Tumor Lysis Syndrome: A Case Report |
| title_full_unstemmed | Concomitant Kinase-Dead BRAF and Oncogenic KRAS Lead to an Aggressive Biologic Behavior and Tumor Lysis Syndrome: A Case Report |
| title_short | Concomitant Kinase-Dead BRAF and Oncogenic KRAS Lead to an Aggressive Biologic Behavior and Tumor Lysis Syndrome: A Case Report |
| title_sort | concomitant kinase dead braf and oncogenic kras lead to an aggressive biologic behavior and tumor lysis syndrome a case report |
| topic | tumor lysis syndrome case report concomitant BRAF and KRAS mutations duodenal mucinous adenocarcinoma NGS - next generation sequencing |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.885814/full |
| work_keys_str_mv | AT royholland concomitantkinasedeadbrafandoncogenickrasleadtoanaggressivebiologicbehaviorandtumorlysissyndromeacasereport AT offirbenishay concomitantkinasedeadbrafandoncogenickrasleadtoanaggressivebiologicbehaviorandtumorlysissyndromeacasereport AT offirbenishay concomitantkinasedeadbrafandoncogenickrasleadtoanaggressivebiologicbehaviorandtumorlysissyndromeacasereport AT iritbenaharon concomitantkinasedeadbrafandoncogenickrasleadtoanaggressivebiologicbehaviorandtumorlysissyndromeacasereport AT iritbenaharon concomitantkinasedeadbrafandoncogenickrasleadtoanaggressivebiologicbehaviorandtumorlysissyndromeacasereport AT iritbenaharon concomitantkinasedeadbrafandoncogenickrasleadtoanaggressivebiologicbehaviorandtumorlysissyndromeacasereport |